Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2026-04-21 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
独立董事变动公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding changes in the company's independent directors, including resignations due to term limits and nominations of new independent directors. It details the compliance and impact of these changes, voting results, and includes biographies of the new nominees. There is no financial data, earnings information, or report publication mentioned. The content focuses solely on board member changes and governance compliance. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 2812 characters, which is consistent with an announcement rather than a full report.
2026-04-21 Chinese
2025年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a '2025 Annual Performance Express Report' (年度业绩快报公告), which indicates it is a preliminary earnings announcement for the full year 2025. It contains key financial data such as revenue, net profit, earnings per share, and asset figures, but explicitly states that the data are preliminary and unaudited, with final audited figures to be disclosed in the full annual report. The document is relatively short (1759 characters) and serves as an initial earnings release rather than a full annual report. It does not contain comprehensive financial statements or detailed management discussion and analysis. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. FY 2025
2026-02-25 Chinese
2026年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement from the company's first extraordinary general meeting (临时股东会决议公告) held on January 15, 2026. It details the meeting attendance, voting results on a specific agenda item regarding related party transactions, and legal opinions confirming the legality and validity of the meeting and resolutions. The document is relatively short (1600 characters) and focuses on the official announcement of the shareholder meeting's resolutions and voting outcomes rather than the full meeting materials or detailed reports. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-01-15 Chinese
股东拟减持股份的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a pre-disclosure announcement regarding a shareholder's planned reduction of shares in the company. It details the shareholder's identity, the number and percentage of shares to be reduced, the method and period of reduction, and compliance with relevant laws and regulations. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about a shareholder's intention to sell shares, which fits the category of Major Shareholding Notification (MRQ). The document length is short and it is not an announcement of a report publication or certification. Therefore, the appropriate classification is MRQ.
2026-01-15 Chinese
江苏世纪同仁律师事务所关于江苏森萱医药股份有限公司2026年第一次临时股东会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of the 2026 first extraordinary general meeting (临时股东会) of Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the legality and validity of the meeting's call, attendance, and resolutions. The document does not contain financial statements or results but is a legal opinion on the shareholder meeting process and outcomes. This type of document is typically associated with announcements or legal opinions related to shareholder meetings rather than the meeting materials themselves or voting results announcements. Given the content and length (2485 characters), it is not a full Annual Report, Interim Report, or Earnings Release. It is not a voting results declaration (DVA) because it is a legal opinion letter rather than an official voting result announcement. It is best classified as a Regulatory Filing (RNS) because it is a legal opinion related to the shareholder meeting, which does not fit other specific categories.
2026-01-15 Chinese
关于召开2026年第一次临时股东会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice for convening the 2026 first extraordinary general meeting (临时股东会) of Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the meeting date, voting methods (onsite and online), agenda items, registration methods, and other procedural information. It does not contain financial statements, audit results, or detailed financial data. It is a formal announcement to shareholders about the meeting and voting procedures, not the meeting materials or results themselves. The document length is 3229 characters, which is relatively short and consistent with a meeting notice. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-12-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.